The results of clinical and economic analysis of treating children with pertussis, scarlet fever and meningococcal disease
DOI:
https://doi.org/10.24959/cphj.14.1292Keywords:
clinical and economic analysis, pertussis, scarlet fever, meningococcal disease, АВС-analysis, VEN-analysisAbstract
The results of clinical and economic analysis of pharmacotherapy of children with pertussis (P), meningococcal disease (MD) and scarlet fever (SF) are given in the article. One hundred and ninety-seven medical histories of hospital patients have been analyzed for the period from 2011 to 2013. The correlation between the patients with P, MD, SF was 17:1,5:1. It has been found that the age group from 1 to 6 years old dominated among infants (43-67%), considerable gender differences were not revealed by pathologies; children with MD sharply dominated in the countryside (80%), as for those with SF, on the contrary, in the urban area (90%). The following medicines were prescribed more often; for treatment of P – the mixture with aminazine, no-spa, amp., tavegil, amp.; for MD therapy – Ringer’s solution, isotonic solution, magnesium sulfate, amp.; for treatment of SF – ascorutin, tab., tavegil, amp., glucose, 5% solution. The most popular АТС-group for treatment of children with SF and МD was the group “Drugs affecting digestive system and metabolism”, it took the second place in pharmacotherapy of infants with P. With the help of АВС-analysis medicines were classified by their contribution in overall costs, which were to average 683,62 UAH per one child with P, 1506,02 UAH per one child with MD, 582,12 UAH per one child with SF in the hospital procurement prices. It has been determined that financial expenses for therapy of ill children were sometimes economically ungrounded due to a great number of medicines with N-index (50-86.2%). Meanwhile, the assessment of reasonability of prescriptions for children with infectious diseases using “formal” VEN-analysis, cannot claim to be objective without review of clinical protocols of diagnostics and treatment in 2004, which presently require updating.
References
Довідково-пошукова система «Лікарські засоби» компанії «Моріон».
Крамарев С.А., Дорошенко Н.С., Закордонец Л.В. // Сучасні інфекції. – 2009. – №3-4. – С. 42-46.
Руководство по диагностике и лечению бактериальных менингитов и менингококковой септицемии у детей и подростков до 16 лет на этапах первичной и специализированной медицинской помощи // Клінічна імунол., алергол., інфектол. – 2011. – №4. – С. 77-88.
Панфілова Г.Л., Немченко А.С., Немченко О.А. Організація фармацевтичної допомоги населенню в умовах медичного страхування: Монографія. – Х., 2009. – 228 с.
Фармакоекономіка: Навч. посіб. для студ. ВНЗ / За ред. Л.В.Яковлєвої. – Вінниця: Нова Книга, 2009. – 208 с.
Campbell H., Amirthalingam G., Andrews N. // Emerg. Infect. Dis. – 2012. – №1. – P. 38-47.
Cassiday P., Tobin-D’Angelo M., Watson J. et al. // J. Med. Microbiol. – 2008. – Vol. 57. – P. 388.
Cathie K., Levin M., Faust S.N. // Arch. Dis. Child. Ed. Pract. – 2008. – Vol. 93. – P. 151-158.
Dr Matthew J. Thompson // The Lancet. – 2006. – Vol. 367, №4. – P. 397-403. 10. Stephens D., Greenwood B., Brandtzaeg P. // The Lancet. – 2007. – Vol. 369, №30. – P. 2196-2210.
Fraser A., Gafter-Gvili A., Paul M., Leibovici L. // The Cochrane Library. – 2009. – Issue 1. – Режим доступу: http://www.thecochranelibrary.com. – Назва з екрану.
James D., Cherry M.D. // Engl. J. Med. – 2012. – Vol. 367. – P. 785-787.
Pelkonen T., Roine I., Monteiro L., Correia M. // Oxford J. Medicine. Clinical Infect. Dis. – 2008. – Vol. 48, №8. – P. 1107-1110.
Pollard A.J., Nadel S., Ninis N. et al. // Arch. Dis. Child. – 2007. – Vol. 92. – P. 283-286.
Sarah S. Long Pertussis / Eds R. Kliegman, R. Behrman, H. Yenson, F. Stanton // «Nelson. Textbook of Pediatrics», 18-th ed. – Р.194-196.
Vidal L., Borok S., Gafter-Gvili A. // The Cochrane Library. – 2009. – Issue 1. –Режим доступу: http:// www.thecochranelibrary.com. – Назва з екрану.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
